Dear Members of the ID-IRI Community,
Below is a summary of the activities and updates from ID-IRI in 2024. Thank you for your continued collaboration and contributions to the research community.
Best wishes
A. Published ID-IRI Projects
1) Sahin M, Yilmaz M, Mert A, et al. Profiles of Primary Brain Abscesses and Their Impact on Survival: An International ID-IRI Study International Journal of Infectious Diseases 2024;1 47: 107228.
2) Filiz M, Erdem H, Ankarali H, et al. Identifying risk factors for blood culture negative infective endocarditis: An international ID-IRI study. New Microbes and New Infections 2024: 60; 101453
3) Sahin M, Yilmaz M, Mert A, et al. Factors Influencing Mortality in COVID-Associated Mucormycosis – The International ID-IRI Study. Medical Mycology 2024; 62(7): myae064
4) Sahin M, Yilmaz, M, Mert A, et al. Factors affecting mortality in COVID-19-associated pulmonary aspergillosis: An international ID-IRI study. Heliyon 2024; 10(14):e34325.
5) Aydin S, Mert A, Yilmaz M, et al. Understanding clinical outcomes and factors affecting mortality in intensive care unit patients with COVID-19-associated Candidemia. Mycoses 2024; 67(1): e13687.
6) Erdem H, Al-Tawfiq JA, Abid M, et al. Infectious causes of fever of unknown origin in developing countries: An international ID-IRI Study. Journal of Intensive Medicine 2024; 28;4(1):94-100
A. Closed ID-IRI projects
1. Inflammatory markers in neutropenic bacteremia (submitted elsewhere).
2. Surgical site infections after cardiac surgery (submitted elsewhere).
3. Analyzing the ID training infrastructure (at data analysis stage).
4. C. auris fungemias (paper is almost finalized).
5. Penicillin-resistant pneumococcal meningitis (at data analysis stage).
6. Elderly bacteremias (at data analysis stage).
7. Peripheral Brucella arthritides (at data analysis stage).
8. Stenotrophomonas maltophilia infections (at data analysis stage).
9. PCP infections (at data analysis stage).
10. Candida scoring project (at data analysis stage)
B. Ongoing ID-IRI Projects
1. The analysis of adenovirus infections. (About to start)
2. Cardiac implantable electronic devices-related endocarditis. (At data collection stage)
3. Dolutegravir/Lamivudine in pregnant HIV-positive individuals. (At data collection stage)